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Abstract
Background: The aim of this study was to investigate if the flattening filter free (FFF) irradiation mode of a linear
accelerator (linac) is advantageous as compared to the flat beam (FF) irradiation mode in intensity modulated
radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) for carcinoma of the hypopharynx / larynx.
Methods: Four treatment plans were created for each of 10 patients for an Elekta Synergy linac with Agility
collimating device, a dual arc VMAT and a nine field step and shoot IMRT each with and without flattening filter.
Plan quality was compared considering target coverage and dose to the organs at risk. All plans were verified by a
2D–ionization-chamber-array and delivery times were compared. Peripheral point doses were determined as a
measure of second cancer risk. The Wilcoxon test was used for statistical analysis with a significance level of 0.05.
Results: Plan quality was similar for all four treatment plans without statistically significant differences of clinical
relevance. The clinical goals were met in all plans for the PTV-SIB (V95% > 95%), the spinal cord (D1ccm < 45 Gy) and
the brain stem (D1ccm < 48 Gy). For the parotids, the goal of D50% < 30 Gy was met in 70% and 60% of the plans
for the left and right parotid respectively, and the V95% of the SIB reached an average of 94%. Delivery times were
similar for FF and FFF and significantly decreased by around 70% for VMAT as compared to IMRT. Peripheral doses
were significantly reduced by 18% in FFF mode as compared to FF and by 26% for VMAT as compared to IMRT.
Lowest peripheral doses were found for VMAT FFF, followed by VMAT FF.
Conclusions: The FFF mode of a linear accelerator is advantageous for the treatment of hypopharynx/larynx
carcinoma only with respect to reduction of second cancer induction in peripheral organs for the combination of
Elekta Synergy linacs and Oncentra® External Beam v4.5 treatment planning system. This might be of interest in a
therapy with curative intent.
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Background
Overall survival of patients with hypopharyngeal and la-
ryngeal carcinoma improved over the last years due to
new cytostatic substances [1, 2] and improved radiation
therapy techniques [3]. Intensity modulated radiotherapy
(IMRT) and volumetric modulated therapy (VMAT)
have emerged as standard external beam radiotherapy
techniques to treat head and neck carcinoma due to sig-
nificant benefits in quality of life and survival as com-
pared to conventional conformal radiation therapy [3].
An increase in loco-regional control may be achieved
using dose escalated fractionation schemes [3, 4]. Simul-
taneous integrated boost techniques are shortening over-
all treatment times and have shown to be a feasible and
save alternative to sequential boost irradiation [5–10].
During the last years, standard linear accelerators with
large field sizes have been installed with an opportunity
to irradiate patients without a flattening filter in the
beam path to increase dose rate and reduce beam-on
time [11]. Since the flattening filter is a source of scatter
radiation, its removal has the positive side effect of low-
ering out-of-field doses [12]. A variety of planning stud-
ies has shown that the flattening filter free (FFF) mode
of a linac allows reducing delivery times in stereotactic
treatments with high fraction doses [13–21]. The chal-
lenge in FFF treatment planning is, however, planning
for large targets due to dose decrease with distance from
the central beam axis. In addition delivery times are in-
fluenced to a larger extent by mechanical constraints of
the gantry and the multi leaf collimator (MLC) in
normo-fractionated treatments with fraction doses
around 2 Gy. First planning studies for larger target
types showed advantages for FFF for some combinations
of target type, treatment technique, planning system and
linac, whereas no advantage or even disadvantages could
be observed in others [22–28], confirming the need of
further investigations depending on target localization
and equipment used, as already pointed out in [12, 29].
The purpose of this study was therefore to evaluate if
the FFF irradiation mode is advantageous with respect
to plan quality, delivery time and peripheral dose as a
measure of excess second cancer risk as compared to
the flat beam (FF) irradiation mode in IMRT and VMAT
for carcinoma of the hypopharynx/larynx for the com-
bination of Elekta Synergy linacs and Oncentra External
Beam v4.5 treatment planning system.
Methods
Patients and dose prescription
CT data of 10 patients with carcinoma of the hypophar-
ynx/larynx were selected from our treatment database
and included in this study. All patients had locally ad-
vanced tumors of Union Internationale Contre le Cancer
(UICC) stage IVa or IVb. A CT scan was used for
delineation of target volumes including information of
MRI and/or PET-CT scans. All patients received bilateral
cervical radiotherapy. Two planning target volumes were
defined as follows: The clinical target volume CTV 1 in-
cludes the primary tumor (gross tumor volume (GTV))
with a 1 cm margin or with anatomically corrected mar-
gins adjacent to uninvolved areas and including the in-
volved lymph nodes as well as the levels with high risk
of involvement. The clinical target volume CTV 2 con-
tains the CTV 1 and the lymph node levels with moder-
ate risk of involvement. The planning target volumes are
derived from the clinical target volumes adding a margin
for systematic and random setup errors and internal mo-
tion of 4 mm and are named SIB (simultaneous inte-
grated boost volume derived from CTV 1) and PTV
(planning target volume derived from CTV 2) respect-
ively. The skin was excluded from the PTV and SIB vol-
umes. The spinal cord, brainstem, parotid glands, and
oral cavity were defined as organs at risk (OAR) [7, 30].
Dose prescription for the simultaneous integrated boost
radiation therapy was an average dose of 66 Gy in 30 frac-
tions of 2.2 Gy to the SIB and 54 Gy in 30 fractions of
1.8 Gy to the PTV-SIB according to [6, 30–32]. Target
coverage, represented by the volume of the SIB and
PTV covered by 95% of the respective prescription
dose (V95%) is generally aimed at 95%. Due to the
proximity of the target volumes to the patient outline,
i.e. the body contour, however, a V95% of 90% is con-
sidered acceptable in this case to avoid severe radio-
dermatitis. For the organs at risk dose volume
tolerances listed in Table 1 in column “Goal” were
chosen as clinical goals. For the parotid salivary
glands, the mean dose should be kept as low as pos-
sible to maintain salivary function [33]. In the litera-
ture a goal of D50% < 30 Gy at least in one gland if
possible depending on the overlap of parotid glands
and PTV has been used for optimization and evalu-
ation [7, 32, 34]. The dose to the oral cavity should
be reduced as much as possible to reduce the risk of
severe mucositis [7, 32].
Linear accelerator and treatment planning system
Treatment planning is performed with Oncentra
External Beam v4.5 (Nucletron, an Elekta Company)
for a Synergy linear accelerator with Agility collimat-
ing device (Elekta AB, Stockholm, Sweden) and 6 MV
photons with flattening filter or without. The FFF
beams were energy-matched to the FF beams with re-
spect to percentage depth dose and quality index as
described in [29, 35]. The multi leaf collimator con-
sists of 80 leaf pairs of 5 mm width at isocenter. The
maximum nominal dose rate is 500 monitor units
(MU) per minute (min) in FF Mode and 1700 MU/
min in FFF mode.
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Treatment planning
For each patient four treatment plans were created,
using the two treatment techniques IMRT and VMAT
each in the two irradiation modes with and without flat-
tening filter, in the following referred to as IMRT FF,
IMRT FFF, VMAT FF, and VMAT FFF. The IMRT plans
consist of nine equispaced beams, minimal segment size
was 9 cm2 and maximal number of segments allowed
was 90. The relatively high number of segments was
allowed due to the complexity of the simultaneous boost
irradiation which requires a steep dose gradient between
the PTV and SIB. This number is used as upper limit
and is not exploited by the optimizer implemented in
Oncentra, if similar plan quality can be achieved with a
lower number of segments. Minimal number of MU per
segment is 4 due to the determined stability of the beam
for 4 MU and higher. The VMAT plans consist of two
full rotations, since it was not possible to achieve the re-
quired plan quality with a single arc. Gantry spacing be-
tween two control points was 4°, collimator angles
ranged from 0° to 45° for both techniques. The isocenter
was located centrally in the PTV for all plans. Suitable
dose volume objectives (DVO) and weights were deter-
mined creating plans in FF mode which met the goals
and then transferred to the FFF plans. Identical DVO
and weights were used for optimization of all plans. All
plans were accepted for treatment by a specialized radi-
ation oncologist and normalized to the average dose in
the SIB.
Dosimetry and delivery
All 40 plans were dosimetrically verified using the
MatriXX Evolution™ 2D–ionization-chamber-array (IBA
Dosimetry, Schwarzenbruck, Germany) set up in
between slabs of a RW3 phantom (PTW, Freiburg,
Germany). All beams were irradiated and evaluated as
complete plan verification. In addition a point dose
measurement was performed 31 cm cranial of the iso-
center using the 0.3 ccm ionization chamber (IC) of type
M23332 in combination with the dosimeter Unidos
(PTW, Freiburg, Germany) in low dose rate mode (range
1.3 mGy/min – 1 Gy/min) to assess peripheral dose as a
measure of excess second cancer risk. The energy de-
pendence is within ±2% in the kV range of the scatter
radiation according to the manual. Measurements of
corresponding FF and FFF plans were performed with-
out repositioning of the IC to avoid uncertainties due to
inaccurate positioning. The measurement setup has been
described in detail in the framework of another study
[36]. During phantom measurements delivery times were
recorded from first beam on to last beam off.
Evaluation
Plan quality was assessed by analysis of the dose volume
histogram (DVH) for the SIB, the PTV and the organs at
risk. Target coverage was represented by the volume of
the SIB and PTV covered by 95% of the respective pre-
scription dose (V95%). The homogeneity index defined as
HI:= (D1% - D99%) /D50% was recorded for the SIB and
for the PTV excluding the SIB (PTV-SIB), to exclude the
high dose region of the SIB from the analysis of the
PTV. The conformity index was defined as as CI:= V95%
2 /
(TV ⋅ PIV) according to Paddick et al. [37]. Here TV
means the volume of the structure, PIV the total volume
covered by 95% of the prescription dose. For the spinal
cord and the brainstem, the dose to 1 ccm (D1ccm) was
evaluated as a measure of clinically relevant maximum
dose. For the parotids the median dose (D50%) was
Table 1 Comparison of plan quality
IMRT VMAT
Parameter Goal FF FFF FF FFF
SIB V95% > 95% 93.7 ± 1.2 93.7 ± 1.3 94.5 ± 1.6 94.2 ± 1.9
HI 0.15 ± 0.03 0.15 ± 0.03 0.14 ± 0.03 0.15 ± 0.04
CI > 0.7 0.83 ± 0.04 0.83 ± 0.04 0.87 ± 0.1 0.83 ± 0.05
PTV - SIB V95% > 95% 98.8 ± 0.3 99.0 ± 0.3 99.0 ± 0.3 98.9 ± 0.6
HI 0.23 ± 0.02 0.22 ± 0.02 0.22 ± 0.03 0.24 ± 0.04
PTV CI > 0.7 0.79 ± 0.03 0.78 ± 0.03 0.76 ± 0.03 0.76 ± 0.03
Spinal Cord D1ccm < 45 Gy 31.7 ± 2.1 31.5 ± 1.7 32.2 ± 1.8 31.7 ± 1.4
Brain Stem D1ccm < 48 Gy 34.6 ± 4.7 34.6 ± 5.0 39.5 ± 4.9 42.1 ± 4.5
Parotid Left D50% < 30 Gy 29.0 ± 4.8 28.3 ± 5.2 29.2 ± 5.6 29.9 ± 6.2
Parotid Right D50% < 30 Gy 30.5 ± 4.8 29.5 ± 4.4 29.7 ± 4.2 29.6 ± 4.3
Oral Cavity V60% 50.8 ± 15.6 51.8 ± 16.0 52.0 ± 15.2 54.0 ± 17.0
Mean values and standard deviation of the dose volume parameters for FF and FFF mode averaged over all patients separated by the treatment technique. Dose
values are given in Gy, volumes in % of the structure volume. HI stands for homogeneity index, CI for conformity index. Bold values indicate statistically significant
superior values in the comparison of FF vs FFF
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recorded and compared to the clinical goal of <30 Gy
[6, 7, 32]. For the oral cavity V60% was analysed. In
addition the number of MU required per fraction dose
and the number of IMRT segments was compared.
For evaluation of plan verification gamma indices as
defined by Low et al. [38] were calculated with a dose
tolerance of 3% of the maximum dose and 3 mm dis-
tance to agreement. The agreement between dose calcu-
lations and measurements is considered acceptable if at
least 95% of the pixels with a dose value of ≥10% of the
maximum dose have a gamma value ≤1 as recom-
mended by the AAPM TG119 [39, 40].
In the low dose region below 1 Gy the excess absolute
risk of developing radiation-induced second cancer
(EAR) has been shown to be linear with dose in an ex-
tensive analysis of the survivors of the atomic bombs of
Hiroshima and Nagasaki [41, 42]. Peripheral IC point
dose measurements were compared for the two irradi-
ation modes FF and FFF for the whole treatment of 30
fractions. Since dose values are well below 1 Gy in this
region, the ratio of peripheral doses in FFF and FF mode
corresponds to the same ratio of EAR in this dose re-
gion. The application of correction factors to achieve ab-
solute doses with high accuracy is not required, since
the goal is to estimate the ratio of EAR in the two irradi-
ation modes and all correction factors cancel out during
division. The uncertainty was estimated to be within
±3%, taking uncertainties due to differences in the en-
ergy spectra of the scatter radiation between FF and FFF
and statistical uncertainty into account. For statistical
analysis the two sided Wilcoxon signed rank test imple-
mented in IBM SPSS® Statistics 23.0 (IBM Corporation)
was used to detect relevant differences of the size of a
standard deviation or larger (effect size 1) with a signifi-
cance level of 0.05.
Results
Since the main subject of the study was the comparison
of the two irradiation modes FF and FFF, details about
statistical significance are listed in the tables for this
comparison. Significant differences between IMRT and
VMAT are mentioned in the text but not listed in detail
in the tables for the sake of clarity.
Plan quality
Acceptable plan quality was achieved with all four treat-
ment plans. Details about DVH parameters averaged
over all patients are given in Table 1. A comparison of
dose distributions and dose volume histograms is shown
in Figs. 1 and 2 for a typical case. The goals listed in
Table 1 were met in all 40 plans for the PTV-SIB, the
spinal cord and the brain stem. For the parotids, the
goals were met in 70% and 60% of the plans for the left
and right parotid respectively, and the V95% of the SIB
reached an average of 94% without significant differ-
ences between FF and FFF. FFF led to significantly
higher target coverage and homogeneity in PTV-SIB
when IMRT was used as treatment technique. Differ-
ences were, however, small with <1% for V95% and 4%
for HI. For VMAT the maximum dose D1ccm to the
brain stem was significantly increased by 7% in FFF
mode, but kept well below the clinical goal of 48 Gy. All
other dose-volume-parameters evaluated in this study
were similar without significant differences between FF
and FFF. Comparison of the two planning techniques
showed significantly higher target coverage and homo-
geneity for VMAT in FF mode and lower OAR and nor-
mal tissue doses for IMRT in both irradiation modes.
Differences in target metrics were, however, marginal be-
tween all four plans.
Dosimetry and delivery
All 40 plans passed the gamma evaluation. No signifi-
cant difference could be observed in the passing rate be-
tween FF and FFF or IMRT and VMAT. Peripheral point
doses were significantly reduced by 18% in FFF mode for
both planning techniques. In comparison of the planning
techniques peripheral doses were significantly lower for
VMAT in both irradiation modes with an average reduc-
tion of 26% in FF mode and 27% in FFF mode as com-
pared to IMRT. The significantly lowest peripheral dose
was found for VMAT FFF. Delivery times increased
slightly but significantly in FFF mode by 4% in case of
IMRT but were similar in both irradiation modes in case
of VMAT. For IMRT around 3 fold delivery times were
required as compared to VMAT in both irradiation
modes. Detailed information about dosimetry and deliv-
ery can be found in Table 2.
Discussion
The aim of this study was to investigate if the FFF irradi-
ation mode of a linear accelerator is advantageous as
compared to FF for IMRT and VMAT of carcinoma of
the hypopharynx and larynx. The results of the study
show, that it was possible to create acceptable treatment
plan quality for IMRT and VMAT without a clear advan-
tage of one of the two irradiation modes: The target
goals and OAR tolerances listed in Table 1 were
achieved in all cases for the PTV-SIB, the spinal cord
and the brain stem. A few significant differences were
observed in the PTV-SIB and the brain stem, but the
clinical goals were achieved in all cases and the differ-
ences are therefore not considered clinically relevant.
The goal of D50% < 30 Gy was achieved averaged over all
plans, but exceeded in 30% and 40% of the plans for the
left and right parotid respectively, without significant
differences between FF and FFF. The reason that the
goal of D50% < 30 Gy was not achieved in all patients
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was a large overlap of the parotid volume and the PTV
in these patients and the fact, that unilateral sparing of
one parotid was in general not applicable due to bilateral
lymph node involvement and therefore bilateral exten-
sion of the PTV and SIB. The results were in concord-
ance with another dose escalation study, which reported
mean and median doses >30 Gy to the parotids for a
similar fractionation scheme [6] and were accepted since
the goal of parotid sparing must not compromise target
coverage as also stated in [33]. Target coverage in the
SIB represented by V95% reached an average of 94% in
both irradiation modes. This was accepted because of
Fig. 1 Comparison of dose distributions. Comparison of dose distributions in one transversal (left) and one sagittal (right) slice for a representative
case. The PTV is drawn in red, SIB dark blue, left parotid orange, right parotid olive, spinal cord cobalt blue, brainstem green, and patient outline
orange. The light blue isodose line represents 95% of the prescription dose to the PTV, the green isodose the 95% of the prescription dose to the SIB
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the proximity of the target to the patient outline and be-
cause special attention was given to the dose conformity
to avoid large high dose volumes outside the targets,
which reached excellent values well above the goal of 0.7
in all cases. Peripheral point dose measurements in the
region well below 1 Gy showed a significant reduction
by 18% in FFF mode. Lowest peripheral doses were mea-
sured for VMAT FFF, with a reduction of 40% as
compared to IMRT FF. Due to the linearity of the excess
absolute risk of developing second cancer with dose in
this dose region, this corresponds to a reduction of the
EAR of 18% and 40%, respectively. This can be explained
by reduced head scatter if the flattening filter is
removed.
Delivery times increased slightly but significantly in
case of IMRT by 22 s from 9:27 min to 9:49 min
Fig. 2 Comparison of dose volume histograms. Comparison of dose volume histograms for the case of Fig. 1. Top IMRT, bottom VMAT. Solid
lines represent FFF, dotted lines FF. The PTV is drawn in red, SIB dark blue, left parotid orange, right parotid olive, spinal cord cobalt blue,
brainstem green, and healthy tissue (patient outline excluding targets) light blue
Table 2 Comparison of delivery
Parameter IMRT FF IMRT FFF VMAT FF VMAT FFF
Passing Rate of Gamma Evaluation (%) 98.5 ± 1.3 97.6 ± 2.0 98.6 ± 0.9 98.9 ± 0.9
Delivery Time (min:s) 9:27 ± 0:34 9:49 ± 0:28 2:52 ± 0:07 2:53 ± 0:05
Measured Peripheral Dose 30 frac (mGy) 209 ± 36 170 ± 34 155 ± 42 127 ± 38
Monitor Units 859 ± 70a 1181 ± 120 571 ± 63a 694 ± 59
Segments (IMRT) 71 ± 4a 79 ± 3 - -
Mean values and standard deviation of delivery time, monitor units and segments for FF and FFF mode averaged over all patients. Bold values indicate
statistically significant superior values in the comparison of FF vs FFF. Bold-italic values indicate best values in the comparison of all planning techniques and
irradiation modes. a indicates statistical significance in the comparison of FF vs FFF without judgement, since the number of monitor units and the number of segments
are no measures of quality
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corresponding to 4% when FFF mode was used. In case
of VMAT delivery times were similar with a mean of
2:52 min for FF and 2:53 min for FFF. The increased de-
livery time for FFF as compared to FF for IMRT can be
explained by the fact that a larger number of segments
is required to achieve a homogeneous dose distribution.
In step and shoot IMRT the beam is turned off during
mechanical movements of the linear accelerator and the
influence of the dose rate is small for fraction doses of
about 2 Gy as compared to higher fraction doses used in
stereotactic treatments. For VMAT, however, the beam
stays on during mechanical movements and the in-
creased number of MU observed in this study with a fac-
tor of 1.3 might theoretically be overcompensated by the
dose rate which is increased by up to a factor of 3.4 in
FFF mode. The maximum dose rate is, however, not
exploited throughout a VMAT treatment, since the gan-
try speed is limited to 1 round per minute. A minimum
irradiation time of 120 s is therefore required for a dual
arc VMAT independent on the maximum dose rate
available. For the equipment used in this study, auto-
sequences are allowed for IMRT but not for VMAT.
Therefore user interaction is required at the end of the
first arc for recording of the first and loading of the sec-
ond arc, which takes additionally around 25 s. Thus the
minimal total delivery time required theoretically for a
dual arc VMAT is around 145 s. This is nearly achieved
in the VMAT FF plans in the study presented here, with
an average of 172 s and a minimum of 159 s. Therefore
the available higher dose rates in FFF mode are not fully
exploited and total delivery times are not further
decreased.
A recently published study evaluated FFF for IMRT
and mArc treatment of hypopharynx carcinoma with a
prescription dose of 50 Gy to the PTV and found no ad-
vantages with respect to plan quality but a slight de-
crease in treatment time [28]. Lowest delivery times
were achieved with mArc FFF ranging from 5:25 to
5:37 min for a 2 Gy fraction dose. Irradiation times were
substantially lower in our study for VMAT in both ir-
radiation modes despite of higher fraction doses of
2.2 Gy to the SIB. The reason for this can be found in
the concept of the mArc technique in which continuous
gantry rotation is combined with a step and shoot like
separation of irradiation and MLC movement. This con-
cept does not allow equally high efficiency as the fully
dynamic VMAT technique used in our study presented
here.
The results of our study confirm that the results of
planning studies for a certain combination of equipment
and tumour site cannot be generalized: A clear advan-
tage for irradiation in FFF mode, as it has previously
been found for the same combination of linear acceler-
ator and treatment planning system for the re-
irradiation of spinal metastases [36], and for a another
treatment planning system and treatment of breast
cancer [27] could not be detected in the study presented
here: Differences in plan quality and delivery were negli-
gible between the two irradiation modes. The only ad-
vantage of FFF mode observed in our study was the
reduction in peripheral dose corresponding to a de-
creased risk of radiation induced second cancers in per-
ipheral organs as it also has been observed for the
treatment of breast cancer in a previous study [43]. This,
however, is of interest only for a therapy with curative
intent, as it is the case e.g. for virus associated tumours.
Conclusions
The flattening filter free mode of a linear accelerator is
advantageous for the treatment of hypopharynx/larynx
carcinoma only with respect to reduction of second can-
cer induction in peripheral organs, which might be of
interest in a therapy with curative intent. No advantage
could be observed with respect to plan quality or deliv-
ery times.
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